Sciclone May Yet Best The Shorts

The bold bears and raging bulls battling over SciClone Pharmaceuticals are likely to engage in another big fight soon. The company's flagship drug, Alpha Thymosin 1, has been under attack by the shorts, who say clinical studies have been limited and "overly optimistic." SciClone argues that its drug is effective against infectious diseases, such as hepatitis.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.